×

Did AbbVie overpay for Pharmacyclics?

7:47 PM ET Thu, 5 March 2015

Raghuram Selvaraju, managing director, Healthcare equity research at MLV & Co, discusses whether AbbVie's acquisition of Pharmacyclics for about $21 billion is a good move.